| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 57,773 | 49,121 | ||
| Marketable securities | 439,616 | 507,706 | ||
| Prepaid expenses and other assets, current | 13,922 | 14,527 | ||
| Total current assets | 511,311 | 571,354 | ||
| Property and equipment, net | 1,155 | 1,151 | ||
| Operating lease right-of-use assets | 2,036 | 2,471 | ||
| Prepaid expenses and other assets, noncurrent | 3,001 | 3,552 | ||
| Total assets | 517,503 | 578,528 | ||
| Accounts payable | 17,950 | 13,157 | ||
| Operating lease liabilities | 473 | 855 | ||
| Accrued expenses and other liabilities, current | 23,457 | 19,542 | ||
| Total current liabilities | 41,880 | 33,554 | ||
| Long-term debt | 74,648 | 74,464 | ||
| Operating lease liabilities, noncurrent | 2,095 | 2,233 | ||
| Total liabilities | 118,623 | 110,251 | ||
| Class a common stock, 0.001 par value 500,000,000 shares authorized as of september 30, 2025 and december 31, 2024 63,894,845 and 63,559,858 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 64 | 64 | ||
| Additionalpaid-incapital | 1,067,703 | 1,057,161 | ||
| Accumulated other comprehensive income | 881 | 527 | ||
| Accumulated deficit | -669,768 | -589,475 | ||
| Total stockholders' equity | 398,880 | 468,277 | ||
| Total liabilities and stockholders' equity | 517,503 | 578,528 | ||
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)